PhD student Queen's University Belfast, United Kingdom
Introduction: Memantine HCl is a clinically approved drug for the treatment of Alzheimer’s disease. It is currently administered orally, which may cause gastrointestinal irritation and reduced patient adherence in the form of irregular dosing. In recent years, transdermal microneedle delivery has attracted increasing interest as a minimally invasive strategy to improve treatment compliance1. Therefore, this study aims to evaluate the feasibility of delivering memantine using two designs of formulations: single- and double-layer dissolving microneedle patch (DMNP).
Learning Objectives:
1. Understand the methodology of safety evaluation in DMNPs
2. Evaluate the impact of repeated DMNP applications on skin integrity and systemic responses
3. Translate preclinical findings to clinical implications for DMNP technology
